source
- Sling Therapeutics raises $123M to fund Phase 3 trial of former Astellas cancer drug for thyroid eye diseaseInvestors have committed $123 million to Sling Therapeutics, a small Michigan biotech focused on eye‑disease treatments. The funding will support a Phase 3 clinical trial of a drug originally deve…
- Skyhawk Therapeutics reports symptom improvement for Huntington's disease in Phase 1/2 extension studySkyhawk Therapeutics announced that its RNA-splicing candidate SKY-0515 showed a measurable improvement in symptoms for patients with Huntington's disease during an extension of its Phase 1/2 trial…